CL2008001970A1 - Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. - Google Patents

Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.

Info

Publication number
CL2008001970A1
CL2008001970A1 CL2008001970A CL2008001970A CL2008001970A1 CL 2008001970 A1 CL2008001970 A1 CL 2008001970A1 CL 2008001970 A CL2008001970 A CL 2008001970A CL 2008001970 A CL2008001970 A CL 2008001970A CL 2008001970 A1 CL2008001970 A1 CL 2008001970A1
Authority
CL
Chile
Prior art keywords
layer
controlled release
tolterodine
bead
microcrystalline cellulose
Prior art date
Application number
CL2008001970A
Other languages
English (en)
Inventor
Den Heuvel Denie Johan Marijn Van
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of CL2008001970A1 publication Critical patent/CL2008001970A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Laminated Bodies (AREA)

Abstract

Perla de liberación controlada que comprende una unidad de núcleo de celulosa microcristalina con un diámetro de 100 a 2000 micrones de un 50-90%, recubrimiento soluble de un polímero vinil pirrolidona de un 2-6%, capa de fármaco que comprende tolterodina, capa de liberación controlada de un polímero independiente del Ph.
CL2008001970A 2007-07-03 2008-07-03 Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva. CL2008001970A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94783307P 2007-07-03 2007-07-03

Publications (1)

Publication Number Publication Date
CL2008001970A1 true CL2008001970A1 (es) 2009-03-27

Family

ID=39876584

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001970A CL2008001970A1 (es) 2007-07-03 2008-07-03 Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.

Country Status (4)

Country Link
US (1) US20090017111A1 (es)
EP (1) EP2173329A1 (es)
CL (1) CL2008001970A1 (es)
WO (1) WO2009003724A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
US20100303920A1 (en) * 2009-05-27 2010-12-02 Johan Hjartstam Aqueous Film Coating Composition / 841
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
CA2835277A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
WO2013128253A1 (en) 2012-02-29 2013-09-06 Itc Limited Polymeric powdered coating composition for making liquid filled polymeric beads and methods thereof
KR102600541B1 (ko) 2016-01-20 2023-11-08 테라비다, 인코포레이티드 다한증을 치료하기 위한 방법 및 조성물
SG11202102349PA (en) 2018-09-28 2021-04-29 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarnic receptor activation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US6005015A (en) * 1997-04-02 1999-12-21 Sealed Air Coporation Polyolefin products and process additives therefor having reduced transfer to substrates
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
NZ504618A (en) * 1998-08-27 2002-09-27 Pharmacia & Upjohn Ab Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EE05191B1 (et) * 1999-11-11 2009-08-17 Pharmacia Ab Farmatseutiline kompositsioon, mis sisaldab tolterodiini, ja selle kasutamine
US6613357B2 (en) * 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
AU2002360717A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Controlled release dosage form having improved drug release properties
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
KR20070012205A (ko) * 2005-07-22 2007-01-25 주식회사종근당 경시 안정성을 갖는 톨테로딘을 함유하는 제어방출형 펠렛

Also Published As

Publication number Publication date
US20090017111A1 (en) 2009-01-15
EP2173329A1 (en) 2010-04-14
WO2009003724A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
CL2008001970A1 (es) Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
MY156248A (en) Controlled release fertilizer composition
PL2539505T3 (pl) Nośnik na bazie włókien celulozowych zawierający warstwę zmodyfikowanego PVA i sposób jego wytwarzania oraz zastosowanie
AR080121A1 (es) Metodo para la elaboracion de un medio de filtro con un aglutinante enriquecido
WO2011054818A3 (de) Neue, nicht kristallisierende methacrylate, deren herstellung und verwendung
DK2223696T3 (da) Mesenkymale CD34- stamceller til anvendelse i sårhelings-genterapi
WO2008099140A3 (en) Scaffold with increased pore size
JP2014509938A5 (es)
PT2323642E (pt) Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea
EP2197575A4 (en) CLAY-LINKED POLYMERIC GELS IN NEW PHYSICAL FORMS, METHODS OF FORMING THEM AND USES THEREOF
JP2009256391A5 (es)
CL2013000731A1 (es) Laminado resistente al fuego que comprende a) un nucleo de laminado de una matriz que comprende resina aglutinante organica, cargas inorganicas y fibras, b) al menos una capa intermedia que contiene al menos una capa de apoyo, c) al menos una capa decorativa; producto precursor de laminado; procedimiento para la produccion de un laminado; y uso del laminado.
NI201100144A (es) Composición farmacéutica sólida que contiene amlopidina y losartán, así como el proceso para producir la misma.
WO2010045542A3 (en) Fused ring heteroaryl kinase inhibitors
WO2008019363A3 (en) 2-alkylbenzoxazole carboxamides as 5ht3 modulators
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
SI2373745T1 (sl) Vodne gošče polnil iz finih delcev, postopek za njihovo pripravo in njihova uporaba za izdelavo papirjev, ki vsebuejo polnila
WO2010044585A3 (en) Piperidine compounds, pharmaceutical composition comprising the same and its use
EP2230274A4 (en) PROCESS FOR PRODUCING ETHYLENE COPOLYMER COMPOSITION AND VINYL ALCOHOL, AND PROCESS FOR PRODUCING ETHYLENE COPOLYMER PELLETS AND VINYL ALCOHOL
JP2008013542A5 (es)
CL2015000375A1 (es) Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras.
EP2502617A4 (en) PROCESS FOR PRODUCING W / O / W EMULSION, METHOD FOR PRODUCING LIPOSOME USING THE METHOD, AND POROUS MEMBRANE FOR USE IN THE METHODS
CL2008000454A1 (es) Un granulo que comprende un nucleo que comprende quetiapina y un agente aglutinante y una capa de recubrimiento que comprende un agente lubricante; procedimiento de preparacion; y composicion farmaceutica.
CL2009000330A1 (es) Composicion farmaceutica que comprende microcapsulas de sabor enmascarado con un nucleo de ranitidina y al menos dos recubrimientos sobre el; tabla de rapida desintegracion oral; metodo para preparar la composicion farmaceutica; metodo para preparar la tableta, util para tratar o prevenir trastornos gastrointestinales.
WO2009014770A3 (en) Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade